The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/ PD-L1 plus anti-CTLA-4): A systematic review and meta-analysis
Số trang: 10
Loại file: pdf
Dung lượng: 1.69 MB
Lượt xem: 12
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
The future of combined immunotherapy (a PD-1/PD-L1 plus a CTLA-4 antagonist) is very bright. However, besides improving efficacy, combined therapy increases treatment-related adverse events (TRAEs). Also, the clinical application is limited in some solid tumors.
Nội dung trích xuất từ tài liệu:
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/ PD-L1 plus anti-CTLA-4): A systematic review and meta-analysis
Nội dung trích xuất từ tài liệu:
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/ PD-L1 plus anti-CTLA-4): A systematic review and meta-analysis
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Adverse events Meta-analysis Combined immune checkpoint inhibitors PD-L1 plus anti-CTLA-4 Treatment-related adverse eventsGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 119 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0